Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26105252 | 1.00 | BACE1 (0.52) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL30639789 | 1.00 | BACE1 (0.52) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL25355242 | 0.91 | BACE1 (0.53) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL5434114 | 0.91 | BACE1 (0.53) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL25356332 | 0.91 | BACE1 (0.53) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL31627392 | 0.91 | BACE1 (0.53) | BACE1TLR2KDM4EPKMMDM2 | |
| SCHEMBL26105646 | 0.88 | TLR2 (0.49) | BACE1TLR2MDM2MDM4TP53 | |
| SCHEMBL26112949 | 0.88 | TLR2 (0.49) | BACE1TLR2MDM2MDM4TP53 | |
| SCHEMBL26105645 | 0.88 | TLR2 (0.49) | BACE1TLR2MDM2MDM4TP53 | |
| SCHEMBL1763640 | 0.85 | IDO1 (0.50) | BACE1TLR2KDM4EPKMMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304550-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4504701-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | Baylor College of Medicine (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2023196455-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304550-A1 | BROMODOMAIN AND EXTRA-TERMINAL (BET) SUBFAMILY BROMODOMAIN 1 (BD1) SELECTIVE INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD1 | BACE1 2642/4885TLR2 1762/4885KDM4E 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.